A Phase II study of the combination of Ofatumumab and Ibrutinib followed by allogeneic bone marrow transplant or consolidation for pretreated high risk patients with Chronic Lymphocytic Leukemia

Promotore
GIMEMA ONLUS
Acronimo
LLC1215
Struttura
Ematologia
Sperimentatore principale
Pietrasanta Daniela
Stato arruolamento
Arruolamento chiuso (continua follow-up)
Linee di ricerca
Linfoma non Hodgkin